Alvotech filed its 2025 Annual Report with the SEC, detailing biosimilar developments and market presence.
Quiver AI Summary
Alvotech has filed its Annual Report 2025 on Form 20-F with the U.S. Securities and Exchange Commission, accessible on both the SEC website and Alvotech's investor relations portal. The company, focused on developing and manufacturing biosimilar medicines, aims to lead the biosimilars market through high-quality, cost-effective products. Alvotech has five approved biosimilars, including those for Humira and Stelara, and a pipeline of nine additional candidates targeting various medical conditions. The company has established strategic partnerships to expand its reach across global markets, including the U.S., Europe, Japan, and parts of South America and Africa. Further details can be found on Alvotech's website.
Potential Positives
- Alvotech has filed its Annual Report 2025 with the SEC, enhancing transparency and compliance with regulatory requirements.
- The company has five biosimilars already approved and marketed globally, indicating a proven track record in the biotechnology sector.
- Alvotech's development pipeline includes nine biosimilar candidates targeting various significant health issues, highlighting its commitment to innovation and growth.
- The establishment of strategic commercial partnerships allows Alvotech to expand its global reach, leveraging local expertise in key markets around the world.
Potential Negatives
- The press release does not provide specific financial results or performance metrics from the Annual Report 2025, which may raise concerns among investors about the company's financial health.
- There is no mention of any new partnerships or advancements in product development, which could imply stagnation in growth or innovation.
- The reminder that information on their website is not part of the press release may detract from the perceived credibility or completeness of the information provided.
FAQ
What is Alvotech's recent financial report submission?
Alvotech has filed its Annual Report 2025 on Form 20-F with the U.S. SEC for the financial year 2025.
Where can I find Alvotech's Annual Report?
The report is available on the SEC’s website and in the investor relations section of Alvotech's website.
What biosimilars has Alvotech developed?
Alvotech has developed biosimilars for Humira®, Stelara®, Simponi®, Eylea®, and Prolia®/Xgeva® among others.
What kinds of diseases are targeted by Alvotech's pipeline?
Alvotech's current pipeline includes biosimilar candidates for autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer.
How does Alvotech support its global reach?
Alvotech has formed strategic commercial partnerships to enhance its global presence and leverage local expertise.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ALVO Hedge Fund Activity
We have seen 29 institutional investors add shares of $ALVO stock to their portfolio, and 37 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- HEIGHTS CAPITAL MANAGEMENT, INC removed 1,090,664 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $8,932,538
- OAKTREE CAPITAL MANAGEMENT LP removed 1,030,020 shares (-65.9%) from their portfolio in Q4 2025, for an estimated $5,284,002
- BLACKROCK, INC. added 369,925 shares (+45.9%) to their portfolio in Q4 2025, for an estimated $1,897,715
- MILLENNIUM MANAGEMENT LLC added 337,417 shares (+1707.7%) to their portfolio in Q4 2025, for an estimated $1,730,949
- GILDER GAGNON HOWE & CO LLC removed 195,345 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $1,599,875
- NORGES BANK removed 180,000 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $923,400
- VANGUARD GROUP INC added 141,948 shares (+3.3%) to their portfolio in Q4 2025, for an estimated $728,193
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$ALVO Analyst Ratings
Wall Street analysts have issued reports on $ALVO in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- UBS issued a "Buy" rating on 11/18/2025
- Morgan Stanley issued a "Overweight" rating on 10/14/2025
To track analyst ratings and price targets for $ALVO, check out Quiver Quantitative's $ALVO forecast page.
$ALVO Price Targets
Multiple analysts have issued price targets for $ALVO recently. We have seen 4 analysts offer price targets for $ALVO in the last 6 months, with a median target of $7.0.
Here are some recent targets:
- Ashwani Verma from UBS set a target price of $6.0 on 03/24/2026
- Glen Santangelo from Barclays set a target price of $4.0 on 03/24/2026
- Niall Alexander from Deutsche Bank set a target price of $8.0 on 11/04/2025
- Thibault Boutherin from Morgan Stanley set a target price of $14.0 on 10/14/2025
Full Release
REYKJAVIK, ICELAND (March 30, 2026) — Alvotech (NASDAQ: ALVO) (the “Company”) has filed its Annual Report 2025 on Form 20-F for the financial year 2025 with the U.S. Securities and Exchange Commission (SEC), incorporating by reference parts of the Alvotech Annual Report 2025. The report is available on the SEC’s website, www.sec.gov , as well as in the investor relations section of Alvotech’s website at https://investors.alvotech.com/financials .
For further information, contact:
Media
Benedikt Stefansson
Sarah MacLeod
[email protected]
Investors
Dr. Balaji V Prasad (US)
Patrik Ling (SE)
Benedikt Stefansson (IS)
[email protected]
About Alvotech
Alvotech is a biotechnology company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in biosimilars by delivering high-quality, cost-effective products and services, enabled by a fully integrated approach and broad in-house capabilities. Five biosimilars are already approved and marketed in multiple global markets, including biosimilars to Humira® (adalimumab), Stelara® (ustekinumab), Simponi® (golimumab), Eylea® (aflibercept) and Prolia®/Xgeva® (denosumab). The current development pipeline includes nine disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. For more information, please visit
https://www.alvotech.com
. None of the information on the Alvotech website shall be deemed part of this press release.
For more information, please visit our investor portal , and our website or follow us on social media on LinkedIn , Facebook , Instagram and YouTube .
